Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

PRINCETON, N.J., Jan. 24, 2013 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today reported results for its fourth quarter and year ended December 31, 2012.  On a GAAP basis, net revenue was $562 million in the fourth quarter and $2,181 million for the full year.  Excluding revenue from facilities that were closed in 2012, pro forma net revenue was $561 million in the fourth quarter and $2,172 million for the full year.  On a GAAP basis, the company reported earnings of $0.61 per diluted share in the fourth quarter.  Excluding losses from facilities that were closed in 2012, restructuring costs and other items during the quarter, the company reported earnings per diluted share of $0.73.  For the full year, diluted earnings per share on a GAAP basis were $1.68.  Excluding losses from facilities closed in 2012, restructuring costs and other charges and favorable income tax developments during the year, the company reported earnings per diluted share of $2.70.

"In 2012, Covance took several important actions which are expected to drive future EPS growth, including reducing our preclinical capacity and overhead cost structure, advancing our strategic IT initiatives, and repurchasing over 10% of our outstanding shares. In addition, our intensified selling efforts led to record adjusted net orders for the year of $2.87 billion, a year-on-year increase of 13.5%, resulting in an adjusted net book-to-bill of 1.32 to 1 for the year," said Joe Herring, Chairman and Chief Executive Officer.  "For the fourth quarter, pro forma revenue of $561 million and pro forma earnings per share of $0.73 were better than expected primarily due to significantly higher kit volumes in central laboratories and continued strength in clinical development. Adjusted net orders in the fourth quarter were a record $769 million, representing an adjusted book-to-bill of 1.37 to 1.

"Late-Stage Development fourth quarter revenues grew 15.7% year-on-year to $345 million. This increase was led by 22% growth in clinical development and 16% growth in central laboratories, which more than offset a decline in our market access services. Late-Stage Development pro forma operating margins increased 130 basis points both year-on-year and sequentially to 21.3%.  In Early Development, pro forma revenue of $216 million and pro forma operating margin of 12.0% declined modestly from the third quarter level on lower demand for discovery support services.

"Looking ahead to 2013, for the full year, we are forecasting mid- to high-single digit year-on-year revenue growth and pro forma diluted earnings per share, which exclude costs from ongoing restructuring activities, in the range of $2.85 to $3.15 (assuming foreign exchange rates remain at year-end 2012 levels).  In the first quarter of 2013, we expect revenue to be up slightly from the fourth quarter level and pro forma earnings per share to be in the range of $0.71 to $0.73 as we forecast an increase in Late-Stage Development net revenues and earnings to be off-set by seasonally-lower first quarter Early Development results." 

Consolidated Results($ in millions except EPS)4Q124Q11ChangeFY12FY11ChangeTotal Revenues

$609.1

$582.4$2,365.7

$2,236.4Less: Reimbursable Out-of-Pockets 

$46.9

$49.9$185.1

$140.5Net Revenues

$562.2

$532.5

5.6%

$2,180.6

$2,095.9

4.0%Operating Income

$43.1

$39.0

10.6%

$115.9

$180.6

(35.8%)Operating Margin

7.7%

7.3%5.3%

8.6%Net Income

$33.9

$21.1

60.3%

$94.7

$132.2

(28.3%)Diluted Earnings per Share

$0.61

$0.35

77.5%

$1.68

$2.16

(22.2%)Revenue from facilities closed in 2012**

$1.5

-$8.8

-Net Revenue, continuing ops*

$560.7

$532.5

5.3%

$2,171.9

$2,236.4

3.6%Restructuring costs and other items

($6.6)

($19.0)($73.1)

($34.7)Loss from facilities closed in 2012**

($2.9)

-($9.3)

-Operating Income, excluding items*

$52.5

$57.9

(9.3%)

$198.2

$215.3

(7.9%)  Operating Margin, excluding items*

9.4%

10.9%9.1%

10.3%Impairment of Equity Investment

-

($12.1)($7.4)

($12.1)Gain on Sale of Investment

-

-$1.5

-Favorable Income Tax Developments

-

$1.8$11.5

$2.5Net Income, excluding items*

$40.3

$44.6

(9.5%)

$151.9

$165.0

(7.9%)Diluted EPS, excluding items*

$0.73

$0.73

0.1%

$2.70

$2.70

(0.1%) * See attached pro forma income statement for reconciliation of 2012 & 2011 GAAP to pro forma amounts.  ** Facilities closed in 2012  include Chandler, Honolulu and Basel.Operating Segment Results Early Development($ in millions)4Q124Q11ChangeFY12FY11ChangeNet Revenues

$217.4

$234.5

(7.3%)

$869.5

$930.6

(6.6%)Operating Income

$18.7

$17.7

5.8%

$4.0

$105.3

(96.2%)Operating Margin

8.6%

7.5%0.5%

11.3%Revenue from facilities closed in 2012**

$1.5

-$8.8

-Net Revenue, continuing ops

$215.9

$234.5

(7.9%)

$860.8

$930.6

(7.5%)Restructuring costs and other items

($4.3)

($15.0)($69.5)

($21.7)Loss from facilities closed in 2012**

($2.9)

-($9.3)

-Operating Income, excluding items

$25.9

$32.6

(20.7%)

$82.7

$127.0

(34.9%)Operating Margin, excluding items

12.0%

13.9%9.6%

13.7%** Facilities closed in 2012 include Chandler, Honolulu and Basel.The Early Development segment includes preclinical toxicology, analytical chemistry, clinical pharmacology, discovery support, and research products.  Net revenues in the fourth quarter of 2012 declined 7.3% year-on-year on a GAAP basis to $217.4 million and 7.9% on a pro forma basis to $215.9 million, due to the following: declines in toxicology, discovery support, and clinical pharmacology; the impact of the sale of environmental services (which had contributed approximately $2.0 million in quarterly revenue); and the closure of sites in 2012. In the quarter, foreign exchange had a 20 basis point year-on-year favorable impact. Sequentially, pro forma revenues decreased $1.9 million on a decline in discovery support. Toxicology revenues were flat sequentially.

GAAP operating income in the fourth quarter of 2012 was $18.7 million, and included $4.3 million in costs associated with our on-going restructuring actions and $2.9 million in losses at closed facilities. GAAP operating income for the fourth quarter of 2011 was $17.7 million, and included $15.0 million in restructuring costs.  Pro forma operating income, excluding these items, was $25.9 million in the fourth quarter of this year, versus $26.9 million last quarter and $32.6 million in the fourth quarter of 2011. Pro forma operating margins were 12.0% for the fourth quarter of this year, versus 12.4% last quarter and compared to 13.9% in the fourth quarter of 2011. Sequentially, pro forma operating income decreased primarily due to a decline in profitability in discovery support.  

Late-Stage Development($ in millions)4Q124Q11ChangeFY12FY11ChangeNet Revenues

$344.8

$298.0

15.7%

$1,311.1

$1,165.4

12.5%Operating Income

$72.7

$58.2

24.8%

$277.6

$226.3

22.7%Operating Margin

21.1%

19.5%21.2%

19.4%Restructuring Costs

($0.7)

($1.3)($1.3)

($5.0)Operating Income, excluding items

$73.4

$59.5

23.3%

$278.8

$231.3

20.6%Operating Margin, excluding items

21.3%

20.0%21.3%

19.8%The Late-Stage Development segment includes central laboratory, Phase IIb-IV clinical development, and market access services.  Net revenues for the fourth quarter of 2012 grew 15.7% year-on-year to $344.8 million, a sequential increase of $20.7 million from the third quarter level. In the quarter, foreign exchange negatively impacted year-on-year revenue growth by 130 basis points. Year-over-year growth was driven by both the continued strong performance in clinical development, where net revenue was up 22%, and a strong increase in central labs, where net revenue was up 16%, which more than offset a year-over-year decline in market access services net revenue. Sequentially, the increase in net revenue was led by central laboratory followed by clinical development and then by market access services.  Central laboratory had an increase in kit volumes for the fifth consecutive quarter.

Operating income for the fourth quarter was $72.7 million on a GAAP basis and $73.4 million on a pro forma basis.  This represents growth of 24.8% and 23.3%, respectively, compared to the fourth quarter of the prior year and a significant increase from the $64.4 million on a GAAP basis and $64.8 million on a pro forma basis last quarter. Pro forma operating margins expanded to 21.3% for the fourth quarter of 2012, up from pro forma operating margins of 20.0% both last quarter and in the fourth quarter of 2011. The year-on-year and sequential increases in profitability were driven by operating leverage in both clinical development and central laboratories, which more than offset increased spending on strategic IT projects.

Corporate InformationThe company reported fourth quarter adjusted net orders of $769 million. Backlog at December 31, 2012 was $6.64 billion compared to $6.37 billion at September 30, 2012 and $6.14 billion at December 31, 2011. Foreign exchange favorably impacted backlog sequentially by $44 million.  In addition, contributing $110 million to fourth quarter backlog growth (but excluded from adjusted net orders) was the extension of a contractual minimum volume commitment and the addition of a small new minimum volume commitment.

Corporate expenses totaled $48.3 million in the fourth quarter of 2012 (including $1.5 million in restructuring costs) compared to $40.9 million last quarter (including $0.5 million in restructuring costs) and $37.0 million in the fourth quarter of 2011 (including $2.7 million in restructuring costs). The largest driver of the sequential increase in corporate expenses was spending on our corporate data center consolidation, one of our strategic IT initiatives, coupled with increased incentive compensation accruals related to stronger business performance toward year end.

Cash and cash equivalents at December 31, 2012 were $493 million compared to $441 million at September 30, 2012 and $389 million at December 31, 2011.  Debt outstanding is now $320 million, originating from borrowings related to our share repurchase program.

Free cash flow (defined as operating cash flow less capital expenditures) for the fourth quarter of 2012 was $61 million, consisting of operating cash flow of $107 million less capital expenditures of $46 million.  Free cash flow for full-year 2012 was $108 million, consisting of operating cash flow of $260 million less capital expenditures of $152 million.Net Days Sales Outstanding (DSO) were 36 days at December 31, 2012 compared to 38 days at both September 30, 2012 and December 31, 2011.

The Company's investor conference call will be webcast on January 25 at 9:00 am ET.  Management's commentary and presentation slides will be available through www.covance.com

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues of approximately $2.2 billion, global operations in more than 30 countries, and more than 11,750 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories,  fluctuations in currency exchange rates, the realization of savings from the Company's announced restructuring actions, the cost and pace of completion of our information technology projects and the realization of benefits therefrom,  and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

Financial Exhibits FollowCOVANCE INC.CONSOLIDATED INCOME STATEMENTSFOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2012 AND 2011(Dollars in thousands, except per share data)Three Months Ended December 31Years Ended December 312012201120122011(UNAUDITED)Net revenues$
562,180$
532,478$   2,180,621$   2,095,938Reimbursable out-of-pocket expenses46,96449,907185,138140,508Total revenues609,144582,3852,365,7592,236,446Costs and expenses:  Cost of revenue395,841371,8521,570,2231,467,051  Reimbursable out-of-pocket expenses46,96449,907185,138140,508  Selling, general and administrative92,82395,752358,854343,044  Depreciation and amortization30,42325,923117,708105,214  Goodwill impairment charge--17,959-Total costs and expenses566,051(a)543,434(c)2,249,882(b)2,055,817(d)Income from operations43,093(a)38,951(c)115,877(b)180,629(d)Other expense, net:  Interest expense, net1,1533393,5061,979  Foreign exchange transaction loss, net1733561,4741,248  Impairment of equity investment-12,1197,37312,119  Gain on sale of investment--(1,459)-  Loss on sale of business--169-Other expense, net1,32612,814(c)11,06315,346(d)Income before taxes and equity investee earnings41,767(a)26,137(c)104,814(b)165,283(d)Taxes on income7,870(a)5,172(c)10,099(b)33,574(d)Equity investee earnings-17517480Net income $
33,897(a)$
21,140(c)$
94,732(b)$
32,189(d)Basic earnings per share$
.63(a)$
.35(c)$
.73(b)$
2.22(d)Weighted average shares outstanding - basic53,698,33459,730,27054,844,64159,629,788Diluted earnings per share$
.61(a)$
.35(c)$
.68(b)$
2.16(d)Weighted average shares outstanding - diluted55,197,96861,080,38756,290,01061,091,354(a) Three months ended December 31, 2012 include, as applicable, $10,191 in restructuring costs ($6,968 net of tax), $3,613 favorable inventory adjustment ($2,502 net of tax) and $2,850 in losses at sites that were closed during the period ($1,966 net of tax).(b) Year ended December 31, 2012 includes, as applicable, $33,930 in restructuring costs ($23,145 net of tax), $21,168 in inventory impairment charges and costs associated with the expected settlement of an inventory supply agreement ($14,645 net of tax), $17,959 of goodwill impairment charges ($17,959net of tax), $7,373 of impairment of equity investment ($7,373 net of tax), $9,274 in losses at sites that were closed during the year ($6,533 net of tax), $1,459 gain on sale of investment ($945 net of tax) and favorable income tax items totaling $11,501.(c) Three months ended December 31, 2011 include, as applicable, $8,667 in restructuring costs ($5,961 net of tax), $10,287 in costs associated with the termination of an inventory supply agreement and related inventory write-down ($7,130 net of tax), $12,119 impairment of equity investment ($12,119 net of tax) and favorable income tax items totaling $1,769.(d) Year ended December 31, 2011 includes, as applicable, $24,369 in restructuring costs ($16,067 net of tax), $10,287 in costs associated with the termination of an inventory supply agreement and related inventory write-down ($7,130 net of tax), $12,119 impairment of equity investment ($12,119 net of tax) and favorable income tax items totaling $2,469.Excluding the impact of restructuring charges, impairment charges, costs associated with the expected settlement of an inventory supply agreement, losses at sites that were closed during the period, gain on sale of investment and favorable tax items, as applicable:Income from operations$
52,521$
57,905$
98,208$
215,285Taxes on income$
,866$
2,804$
41,135$
47,502Net income $
40,329$
44,581$
51,941$
5,036Basic earnings per share$
.75$
.75$
2.77$
2.77Diluted earnings per share$
.73$
.73$
2.70$
2.70COVANCE INC.CONSOLIDATED BALANCE SHEETSDECEMBER 31, 2012 and DECEMBER 31, 2011(Dollars in thousands)December 31December 3120122011ASSETSCurrent Assets:Cash & cash equivalents$
492,824$
389,103Accounts receivable, net339,558312,127Unbilled services136,878114,095Inventory49,27074,698Deferred income taxes44,90352,078Income taxes receivable3,642-Prepaid expenses and other current assets167,629144,809Total Current Assets1,234,7041,086,910Property and equipment, net891,319849,551Goodwill109,820127,779Other assets52,49943,768Total Assets$   2,288,342$   2,108,008LIABILITIES and STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable$
34,430$
36,393Accrued payroll and benefits144,681142,229Accrued expenses and other current liabilities127,686119,308Unearned revenue255,776202,210Short-term debt 320,00030,000Income taxes payable-6,889Total Current Liabilities882,573537,029Deferred income taxes27,91242,295Other liabilities70,66570,889Total Liabilities981,150650,213Stockholders' Equity:Common stock791781Paid-in capital744,114689,584Retained earnings1,600,6261,505,894Accumulated other comprehensive income28,5204,622Treasury stock(1,066,859)(743,086)Total Stockholders' Equity1,307,1921,457,795Total Liabilities and Stockholders'  Equity$   2,288,342$   2,108,008 COVANCE INC.CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011(Dollars in thousands)Years Ended December 3120122011Cash flows from operating activities:  Net income$
94,732$
32,189  Adjustments to reconcile net income to net cash provided byoperating activities:Depreciation and amortization117,708105,214Non-cash impairment charges41,73612,119Non-cash compensation expense associated with employee benefitand stock compensation plans40,75940,057Deferred income tax benefit(8,404)(6,128)Gain on sale of investment(1,459)-Loss on sale of business169-Loss on disposal of property and equipment1,1811,618Equity investee earnings(17)(480)Changes in operating assets and liabilities, net of businesses soldand acquired:Accounts receivable(28,541)(50,754)Unbilled services(23,419)(23,366)Inventory10,9188,226Accounts payable(1,963)2,297Accrued liabilities8,20556,409Unearned revenue54,99815,909Income taxes(10,522)(21,070)Other assets and liabilities, net(35,920)(28,762)Net cash provided by operating activities260,161243,478Cash flows from investing activities:  Capital expenditures(151,679)(134,633)  Proceeds from sale of investment4,682-  Other, net1,017(219)Net cash used in investing activities(145,980)(134,852)Cash flows from financing activities:  Net borrowings (repayments) under revolving credit facility290,000(5,000)  Repayments under long-term debt-(97,500)  Stock issued under employee stock purchase and option plans13,7729,325  Purchase of treasury stock(323,773)(8,810)Net cash used in financing activities(20,001)(101,985)Effect of exchange rate changes on cash9,5415,239Net change in cash and cash equivalents103,72111,880Cash and cash equivalents, beginning of period389,103377,223Cash and cash equivalents, end of period$
492,824$
389,103 COVANCE INC.GAAP to Pro Forma ReconciliationQ4 2012(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring Activities (1)Other
Items (2)Operating Results at Sites Wound-Down (3)Pro FormaNet revenues$
562,180$
(1,498)$
560,682Reimbursable out-of-pocket expenses46,96446,964Total revenues609,144--(1,498)607,646Costs and expenses:  Cost of revenue395,8413,613(3,697)395,757  Reimbursable out-of-pocket expenses46,96446,964  Selling, general and administrative92,823(9,013)(117)83,693  Depreciation and amortization30,423(1,178)(534)28,711  Goodwill impairment charge---Total costs and expenses566,051(10,191)3,613(4,348)555,125Income from operations43,09310,191(3,613)2,85052,521Other expense, net:  Interest expense, net1,1531,153  Foreign exchange transaction loss, net173173  Impairment of equity investment--  Gain on sale of investment--  Loss on sale of business--Other expense, net1,326---1,326Income before taxes and equity investee earnings41,76710,191(3,613)2,85051,195Taxes on income7,8703,223(1,111)88410,866Equity investee earnings--Net income $
33,897$
,968$
(2,502)$
,966$
40,329Basic earnings per share$
.63$
.13$
(0.05)$
.04$
.75Weighted average shares outstanding - basic53,698,33453,698,33453,698,33453,698,33453,698,334Diluted earnings per share$
.61$
.13$
(0.05)$
.04$
.73Weighted average shares outstanding - diluted55,197,96855,197,96855,197,96855,197,96855,197,968(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.(2) Reduction of inventory impairment based upon determination of actual impaired inventory.(3) Represents results of operations at sites that were closed during the period. COVANCE INC.GAAP to Pro Forma ReconciliationQ4 2011(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring Activities (1)Other
Charges (2)Income Tax Items (3)Pro FormaNet revenues$
532,478$
532,478Reimbursable out-of-pocket expenses49,90749,907Total revenues582,385---582,385Costs and expenses:  Cost of revenue371,852371,852  Reimbursable out-of-pocket expenses49,90749,907  Selling, general and administrative95,752(8,754)(10,287)76,711  Depreciation and amortization25,9238726,010Total costs and expenses543,434(8,667)(10,287)-524,480Income from operations38,9518,66710,287-57,905Other expense, net:  Interest expense, net339339  Foreign exchange transaction loss, net356356  Impairment of equity investment12,119(12,119)-Other expense, net12,814-(12,119)-695Income before taxes and equity investee earnings26,1378,66722,406-57,210Tax expense5,1722,7063,1571,76912,804Equity investee earnings175175Net income $
21,140$
5,961$
9,249$
(1,769)$
44,581Basic earnings per share$
.35$
.10$
.32$
(0.03)$
.75Weighted average shares outstanding - basic59,730,27059,730,27059,730,27059,730,27059,730,270Diluted earnings per share$
.35$
.10$
.32$
(0.03)$
.73Weighted average shares outstanding - diluted61,080,38761,080,38761,080,38761,080,38761,080,387(1) Represents costs incurred in connection with capacity rationalization, streamlining operations and other cost reduction actions.(2) Represents costs incurred in connection with termination of an inventory supply agreement and related inventory write-down and an impairment of a related equity investment.(3) Represents favorable resolutions of income tax matters. COVANCE INC.GAAP to Pro Forma ReconciliationFor the year ended December 31, 2012(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring Activities (1)Other
Items (2)Operating Results at Sites Wound-Down (3)Income Tax Items (4)Pro FormaNet revenues$
2,180,621$
(8,754)$  2,171,867Reimbursable out-of-pocket expenses185,138185,138Total revenues2,365,759--(8,754)-2,357,005Costs and expenses:  Cost of revenue1,570,223(21,168)(15,180)1,533,875  Reimbursable out-of-pocket expenses185,138185,138  Selling, general and administrative358,854(30,460)(501)327,893  Depreciation and amortization117,708(3,470)(2,347)111,891  Goodwill impairment charge17,959(17,959)-Total costs and expenses2,249,882(33,930)(39,127)(18,028)-2,158,797Income from operations115,87733,93039,1279,274-198,208Other expense, net:  Interest expense, net3,5063,506  Foreign exchange transaction loss, net1,4741,474  Impairment of equity investment7,373(7,373)-  Gain on sale of investment(1,459)1,459-  Loss on sale of business169169Other expense, net11,063-(5,914)--5,149Income before taxes and equity investee earnings104,81433,93045,0419,274-193,059Taxes on income10,09910,7856,0092,74111,50141,135Equity investee earnings1717Net income $
94,732$
23,145$
39,032$
,533$
(11,501)$
51,941Basic earnings per share$
.73$
.42$
.71$
.12$
(0.21)$
2.77Weighted average shares outstanding - basic54,844,64154,844,64154,844,64154,844,64154,844,64154,844,641Diluted earnings per share$
.68$
.41$
.69$
.12$
(0.20)$
2.70Weighted average shares outstanding - diluted56,290,01056,290,01056,290,01056,290,01056,290,01056,290,010(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.(2) Consists of inventory impairment and costs associated with the expected settlement of an inventory supply agreement ($21,168), goodwill impairment ($17,959), impairment of equity investment ($7,373) and a gain on the sale of an investment $1,459.(3) Represents results of operations at sites that were closed during the period.(4) Primarily represents favorable resolutions of income tax matters. COVANCE INC.GAAP to Pro Forma ReconciliationFor the year ended December 31, 2011(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring Activities (1)Other
Charges (2)Income Tax Items (3)Pro FormaNet revenues$  2,095,938$  2,095,938Reimbursable out-of-pocket expenses140,508140,508Total revenues2,236,446---2,236,446Costs and expenses:  Cost of revenue1,467,0511,467,051  Reimbursable out-of-pocket expenses140,508140,508  Selling, general and administrative343,044(22,592)(10,287)310,165  Depreciation and amortization105,214(1,777)103,437Total costs and expenses2,055,817(24,369)(10,287)-2,021,161Income from operations180,62924,36910,287-215,285Other expense, net:  Interest expense, net1,9791,979  Foreign exchange transaction loss, net1,2481,248  Impairment of equity investment12,119(12,119)-Other expense, net15,346-(12,119)-3,227Income before taxes and equity investee earnings165,28324,36922,406-212,058Tax expense33,5748,3023,1572,46947,502Equity investee earnings480480Net income $
32,189$
,067$
9,249$
(2,469)$
5,036Basic earnings per share$
2.22$
.27$
.32$
(0.04)$
2.77Weighted average shares outstanding - basic59,629,78859,629,78859,629,78859,629,78859,629,788Diluted earnings per share$
2.16$
.26$
.32$
(0.04)$
2.70Weighted average shares outstanding - diluted61,091,35461,091,35461,091,35461,091,35461,091,354(1) Represents costs incurred in connection with capacity rationalization, streamlining operations and other cost reduction actions.(2) Represents costs incurred in connection with termination of an inventory supply agreement and related inventory write-down and an impairment of a related equity investment.(3) Represents favorable resolutions of income tax matters. 


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en marcha una ... compartir sus mejores prácticas por el mundo y tratar ... Europa, África, Asia y Estados ... combina la transmisión en vivo con mensajería instantánea y ... "Imagine un médico de Medicines sans Frontieres ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The Georgia State University College of Law ... Atlanta Urban Design Commission. , The annual award recognizes projects, programs, individuals and organizations ... the preservation of its physical heritage and the balance between the old and the ...
(Date:5/25/2016)... The Netherlands (PRWEB) , ... May 25, 2016 , ... ... unprecedented freedom of movement to motion capture, all by utilizing a common Wi-Fi network ... allows users to transmit data from any location with Wi-Fi, and use a mobile ...
(Date:5/25/2016)... ... , ... One Florida-based plastic surgeon’s enthusiasm is proving to be contagious among ... May 13th on Vanity Fair. In fact, as the article explains, more than a ... more than 800,000 Snapchat fans. Commenting on this trend, Dr. Michael Salzhauer, also known ...
(Date:5/25/2016)... ... 2016 , ... The Bank of America Charitable Foundation has awarded a grant ... a pathway to employment and successful careers in healthcare. On Wednesday, May 4th, Rick ... and CEO of Medisend, parent organization and home of the General Myers Veterans Program. ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies published today by ... across 15 states. The outcomes examined in these studies include recovery of physical ... satisfaction with medical care. , “The goal of the studies is to provide ...
Breaking Medicine News(10 mins):